AFMD News and Press, Affimed N.V. From 08/23/21

HEIDELBERG, Germany, Aug. 23, 2021 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that it will release second quarter 2021 results on Wednesday, September 8, 20...

AFM24 is an innate cell engager with a novel and distinctive mechanism of action, designed to address the need of broader patient populations than current EGFR-targeting treatments. Preclinical data demonstrate AFM24’s activation of the innate immune system, acting independen...

Gainers: [[NRXP]] +10.1%. [[PDD]] +6.6%. [[TLSA]] +6.3%. [[AFMD]] +4.4%. [[UXIN]] +3.8%.Losers: [[ACOR]] -3.8%. [[IPA]] -2.8%. [[SNCR]] -2.5%. [[PRVB]] -2.3%. [[INCY]] -3.3%. For further details see: NRXP, PDD, ACOR and IPA among after-hours movers

Whether penny stocks or blue-chips, analysts have high hopes for biotech stocks right now. Thanks to the growing optimism for new treatments & novel discoveries, this is one of the hottest industries in the stock market today. Does it come with plenty of risks? Of course, and this is on...

Affimed recently reported their Q1 earnings that revealed a solid beat on EPS and revenue. However, the company also announced that Genentech has stopped one of their partnered programs. Following the Genentech announcement, the share price has been under pressure. I believe the marke...

Affimed did well in the last 12 months, but has been seeing a correction lately. Given a "data rich" 2021, the correction is not correct. Current prices look attractive. For further details see: Affimed: Current Fall And Future Prospects

Affimed N.V. (AFMD) Q1 2021 Earnings Conference Call July 1, 2021 08:30 AM ET Company Participants Alexander Fudukidis - Head of Investor Relations Adi Hoess - Chief Executive Officer Arndt Schottelius - Chief Scientific Officer Angus Smith - Chief Financial Officer Andreas Harstrick - Chief ...

Affimed (AFMD) posted first-quarter revenue that beat Wall Street estimates, and said that it expects the company's cash and cash equivalents to support operations into the second half of 2023.The company's revenue during the period more than doubled to €11.66M, beating analysts' ...

Affimed (AFMD): Q1 GAAP EPS of -€0.01 beats by €0.09.Revenue of €11.66M (+126.8% Y/Y) beats by €2.46M.Cash and cash equivalents as of March 31, 2021, were approximately €240.7 million with anticipated cash runway into 2H23.Shares +5% PM.Press Release ...

AFM13 monotherapy: Reported positive outcome from the preplanned interim analysis for the registration-directed trial in PTCL; enrollment expected to be completed in the first half of 2022. AFM13 combination with NK cells: Announced 100% objective response rate in the first four respo...